On Monday, Apellis Pharmaceuticals Inc (NASDAQ: APLS) opened lower -1.77% from the last session, before settling in for the closing price of $20.34. Price fluctuations for APLS have ranged from $16.98 to $49.06 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 92.54% over the past five years. Company’s average yearly earnings per share was noted 36.81% at the time writing. With a float of $104.61 million, this company’s outstanding shares have now reached $124.50 million.
Let’s look at the performance matrix of the company that is accounted for 710 employees. In terms of profitability, gross margin is 84.82%, operating margin of -21.11%, and the pretax margin is -25.18%.
Apellis Pharmaceuticals Inc (APLS) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Apellis Pharmaceuticals Inc is 16.77%, while institutional ownership is 99.15%. The most recent insider transaction that took place on Mar 17 ’25, was worth 4,543. In this transaction VP/Chief Accounting Officer of this company sold 183 shares at a rate of $24.82, taking the stock ownership to the 47,955 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Officer proposed sale 183 for $24.82, making the entire transaction worth $4,543.
Apellis Pharmaceuticals Inc (APLS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 36.81% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Check out the current performance indicators for Apellis Pharmaceuticals Inc (APLS). In the past quarter, the stock posted a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.60, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach 0.14 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Apellis Pharmaceuticals Inc (NASDAQ: APLS) saw its 5-day average volume 2.87 million, a positive change from its year-to-date volume of 2.08 million. As of the previous 9 days, the stock’s Stochastic %D was 85.73%. Additionally, its Average True Range was 1.15.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 16.03%, which indicates a significant decrease from 79.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.24% in the past 14 days, which was lower than the 54.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.20, while its 200-day Moving Average is $29.81. Nevertheless, the first resistance level for the watch stands at $20.44 in the near term. At $20.91, the stock is likely to face the second major resistance level. The third major resistance level sits at $21.22. If the price goes on to break the first support level at $19.66, it is likely to go to the next support level at $19.35. The third support level lies at $18.88 if the price breaches the second support level.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
There are currently 125,682K shares outstanding in the company with a market cap of 2.51 billion. Presently, the company’s annual sales total 781,370 K according to its annual income of -197,880 K. Last quarter, the company’s sales amounted to 212,530 K and its income totaled -36,350 K.
